A citation-based method for searching scientific literature

Pasi A Jänne, Alice T Shaw, José Rodrigues Pereira, Gaëlle Jeannin, Johan Vansteenkiste, Carlos Barrios, Fabio Andre Franke, Lynda Grinsted, Victoria Zazulina, Paul Smith, Ian Smith, Lucio Crinò. Lancet Oncol 2013
Times Cited: 499







List of co-cited articles
928 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Pasi A Jänne, Michel M van den Heuvel, Fabrice Barlesi, Manuel Cobo, Julien Mazieres, Lucio Crinò, Sergey Orlov, Fiona Blackhall, Juergen Wolf, Pilar Garrido,[...]. JAMA 2017
221
43

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
G R Blumenschein, E F Smit, D Planchard, D-W Kim, J Cadranel, T De Pas, F Dunphy, K Udud, M-J Ahn, N H Hanna,[...]. Ann Oncol 2015
215
30

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Jonathan M Ostrem, Ulf Peters, Martin L Sos, James A Wells, Kevan M Shokat. Nature 2013
24

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Jude Canon, Karen Rex, Anne Y Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G Knutson, Neelima Koppada,[...]. Nature 2019
757
21

Drugging the undruggable RAS: Mission possible?
Adrienne D Cox, Stephen W Fesik, Alec C Kimmelman, Ji Luo, Channing J Der. Nat Rev Drug Discov 2014
17

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Matthew R Janes, Jingchuan Zhang, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Xin Guo, Yuching Chen, Anjali Babbar, Sarah J Firdaus, Levan Darjania,[...]. Cell 2018
536
17

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
708
17

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Jill Hallin, Lars D Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David M Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R Baer, Joshua A Ballard,[...]. Cancer Discov 2020
461
16

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.
Piro Lito, Martha Solomon, Lian-Sheng Li, Rasmus Hansen, Neal Rosen. Science 2016
357
15

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Ferdinandos Skoulidis, Lauren A Byers, Lixia Diao, Vassiliki A Papadimitrakopoulou, Pan Tong, Julie Izzo, Carmen Behrens, Humam Kadara, Edwin R Parra, Jaime Rodriguez Canales,[...]. Cancer Discov 2015
494
15

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger,[...]. N Engl J Med 2020
531
15

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
Snjezana Dogan, Ronglai Shen, Daphne C Ang, Melissa L Johnson, Sandra P D'Angelo, Paul K Paik, Edyta B Brzostowski, Gregory J Riely, Mark G Kris, Maureen F Zakowski,[...]. Clin Cancer Res 2012
372
14


A comprehensive survey of Ras mutations in cancer.
Ian A Prior, Paul D Lewis, Carla Mattos. Cancer Res 2012
14

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Matthew P Patricelli, Matthew R Janes, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Linda V Kessler, Yuching Chen, Jeff M Kucharski, Jun Feng, Tess Ely,[...]. Cancer Discov 2016
399
14

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Jeffrey A Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R Guimaraes, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A Perera, Youngchul Song,[...]. Nat Med 2008
14

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
C A Carter, A Rajan, C Keen, E Szabo, S Khozin, A Thomas, C Brzezniak, U Guha, L A Doyle, S M Steinberg,[...]. Ann Oncol 2016
61
22

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
13

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
13


A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.
John D Hainsworth, Cristina L Cebotaru, Vladimir Kanarev, Tudor E Ciuleanu, Danail Damyanov, Phillip Stella, Hristo Ganchev, Gillian Pover, Clive Morris, Valentina Tzekova. J Thorac Oncol 2010
131
13

A combinatorial strategy for treating KRAS-mutant lung cancer.
Eusebio Manchado, Susann Weissmueller, John P Morris, Chi-Chao Chen, Ramona Wullenkord, Amaia Lujambio, Elisa de Stanchina, John T Poirier, Justin F Gainor, Ryan B Corcoran,[...]. Nature 2016
258
12

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
David Planchard, Benjamin Besse, Harry J M Groen, Pierre-Jean Souquet, Elisabeth Quoix, Christina S Baik, Fabrice Barlesi, Tae Min Kim, Julien Mazieres, Silvia Novello,[...]. Lancet Oncol 2016
486
11


Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Eva Dombi, Andrea Baldwin, Leigh J Marcus, Michael J Fisher, Brian Weiss, AeRang Kim, Patricia Whitcomb, Staci Martin, Lindsey E Aschbacher-Smith, Tilat A Rizvi,[...]. N Engl J Med 2016
322
11

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.
Chong Sun, Sebastijan Hobor, Andrea Bertotti, Davide Zecchin, Sidong Huang, Francesco Galimi, Francesca Cottino, Anirudh Prahallad, Wipawadee Grernrum, Anna Tzani,[...]. Cell Rep 2014
221
11

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
11

RAS Proteins and Their Regulators in Human Disease.
Dhirendra K Simanshu, Dwight V Nissley, Frank McCormick. Cell 2017
729
11

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
10

RAS oncogenes: weaving a tumorigenic web.
Yuliya Pylayeva-Gupta, Elda Grabocka, Dafna Bar-Sagi. Nat Rev Cancer 2011
10

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.
Sang Min Lim, Kenneth D Westover, Scott B Ficarro, Rane A Harrison, Hwan Geun Choi, Michael E Pacold, Martin Carrasco, John Hunter, Nam Doo Kim, Ting Xie,[...]. Angew Chem Int Ed Engl 2014
218
10


Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
460
10

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.
David R Gandara, Natasha Leighl, Jean-Pierre Delord, Fabrice Barlesi, Jaafar Bennouna, Gerald Zalcman, Jeffrey R Infante, Karen L Reckamp, Karen Kelly, Frances A Shepherd,[...]. J Thorac Oncol 2017
26
38

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.
C Mascaux, N Iannino, B Martin, M Paesmans, T Berghmans, M Dusart, A Haller, P Lothaire, A-P Meert, S Noel,[...]. Br J Cancer 2005
445
10

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
10

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, Jian Su, Zhi Xie, Si-Yang Liu, Hai-Yan Tu, Hua-Jun Chen, Yue-Li Sun, Qing Zhou,[...]. Clin Cancer Res 2017
488
10

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.
Jenny Y Xue, Yulei Zhao, Jordan Aronowitz, Trang T Mai, Alberto Vides, Besnik Qeriqi, Dongsung Kim, Chuanchuan Li, Elisa de Stanchina, Linas Mazutis,[...]. Nature 2020
170
10

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
Gregory J Riely, Melissa L Johnson, Chanoa Medina, Naiyer A Rizvi, Vincent A Miller, Mark G Kris, M Catherine Pietanza, Christopher G Azzoli, Lee M Krug, William Pao,[...]. J Thorac Oncol 2011
98
9

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
David Planchard, Tae Min Kim, Julien Mazieres, Elisabeth Quoix, Gregory Riely, Fabrice Barlesi, Pierre-Jean Souquet, Egbert F Smit, Harry J M Groen, Ronan J Kelly,[...]. Lancet Oncol 2016
262
9

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.
Ryan B Corcoran, Katherine A Cheng, Aaron N Hata, Anthony C Faber, Hiromichi Ebi, Erin M Coffee, Patricia Greninger, Ronald D Brown, Jason T Godfrey, Travis J Cohoon,[...]. Cancer Cell 2013
284
9

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Nathan T Ihle, Lauren A Byers, Edward S Kim, Pierre Saintigny, J Jack Lee, George R Blumenschein, Anne Tsao, Suyu Liu, Jill E Larsen, Jing Wang,[...]. J Natl Cancer Inst 2012
336
9

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.
Kathryn C Arbour, Emmett Jordan, Hyunjae Ryan Kim, Jordan Dienstag, Helena A Yu, Francisco Sanchez-Vega, Piro Lito, Michael Berger, David B Solit, Matthew Hellmann,[...]. Clin Cancer Res 2018
189
9

KRAS-Mutant non-small cell lung cancer: From biology to therapy.
Irene Ferrer, Jon Zugazagoitia, Stephan Herbertz, William John, Luis Paz-Ares, Gerald Schmid-Bindert. Lung Cancer 2018
144
9

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Gregory J Riely, Mark G Kris, Daniel Rosenbaum, Jenifer Marks, Allan Li, Dhananjay A Chitale, Khedoudja Nafa, Elyn R Riedel, Meier Hsu, William Pao,[...]. Clin Cancer Res 2008
395
9

KRAS: Reasons for optimism in lung cancer.
C R Lindsay, M Jamal-Hanjani, M Forster, F Blackhall. Eur J Cancer 2018
37
24

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
P A Jänne, I Smith, G McWalter, H Mann, B Dougherty, J Walker, M C M Orr, D R Hodgson, A T Shaw, J R Pereira,[...]. Br J Cancer 2015
61
14

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Alex A Adjei, Roger B Cohen, Wilbur Franklin, Clive Morris, David Wilson, Julian R Molina, Lorelei J Hanson, Lia Gore, Laura Chow, Stephen Leong,[...]. J Clin Oncol 2008
476
9

Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Adrienne D Cox, Channing J Der, Mark R Philips. Clin Cancer Res 2015
238
9

Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition.
Meagan B Ryan, Ferran Fece de la Cruz, Sarah Phat, David T Myers, Edmond Wong, Heather A Shahzade, Catriona B Hong, Ryan B Corcoran. Clin Cancer Res 2020
137
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.